Targovax ASA: second quarter and first half year 2021 results
Oslo, Norway, 18 August 2021 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its second quarter and first half year 2021 results. Targovax’s management will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below). FIRST HALF YEAR HIGHLIGHTS ·Reported class-leading median overall survival in Targovax’s ONCOS-102 trial in mesothelioma at the 24-month follow-up ·Received Fast-Track